Q

    Quince Therapeutics, Inc. (QNCX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.57
    -1.18 (-3.50%)

    Market Cap: $34.33M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(10/26)
    Avg Surprise
    -51.76%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.10
    Range$-1.37 - $-0.83
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-54.00-4809.1%
    60d ago$-54.00-4809.1%
    30d ago$-1.39-25.9%
    7d ago$-1.40-27.6%
    Current$-1.10
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$12.13
    Range$7.79 - $14.83
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$12.13---
    Sep 26EST
    		-$-1.10---
    Jun 26
    		$-12.31N/A+62.99%Beat+81.1%
    Mar 26
    		$-152.00$-45.00-237.78%Miss-44605.9%
    Dec 25
    		$-0.41$-0.18-123.35%Miss+99.3%
    Sep 25
    		$-50.00$-44.50-12.36%Miss-92.3%
    Jun 25
    		$-65.02$-46.50-39.83%Miss-10005.7%
    Mar 25
    		$-0.34$-0.23-47.83%Miss-56.6%
    Dec 24
    		$-56.00$-20.00-180.00%Miss-25354.5%
    Sep 24
    		$-26.00$-20.00-30.00%Miss-17432.0%
    Jun 24
    		$-0.64$0.00N/ABeat-373.1%
    Mar 24
    		$-0.22$0.00N/ABeat+36.5%
    Dec 23
    		$-0.22$-0.28+21.43%Beat-46.7%
    Sep 23
    		$-0.15N/AN/ABeat+99.7%
    Jun 23
    		$-0.14$0.00N/AMiss+99.9%
    Mar 23
    		$-0.34$-0.31-10.54%Miss+99.8%
    Dec 22
    		$-0.15$-0.29+47.84%Beat+80.8%
    Sep 22
    		$-44.00$-56.72+22.43%Beat+69.9%
    Jun 22
    		$-102.00$-56.05-81.98%Miss+31.1%
    Mar 22
    		$-144.00$-111.91-28.67%Miss+7.7%
    Dec 21
    		$-0.78$-0.65-20.00%Miss-13.0%
    Sep 21
    		$-146.00$-148.80+1.88%Beat+0.0%
    Jun 21
    		$-148.00$-151.65+2.41%Beat-23.3%
    Mar 21
    		$-156.00$-138.54-12.60%Miss-27.9%
    Dec 20
    		$-0.69$-0.73+5.48%Beat-97.1%
    Sep 20
    		$-146.00$-121.67-20.00%Miss-97.3%
    Jun 20
    		$-120.00$-121.63+1.34%Beat-5.3%
    Mar 20
    		$-122.00$-88.93-37.19%Miss-7477.6%
    Dec 19
    		$-0.35$-0.40+12.50%Beat-
    Sep 19
    		$-74.00$-74.35+0.47%Beat-
    Jun 19
    		$-114.00$-80.00-42.50%Miss-
    Mar 19
    		$-1.61$-0.23-600.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.15EV/EBITDA1.44x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-153.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio14.52xQuick Ratio14.52x
    Trading Statistics
    Beta1.26Avg Volume28.21K
    52-Week High$910.0052-Week Low$15.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$32.81
    SMA 20$31.96
    SMA 50$24.15
    SMA 200$181.73
    EMA 10$32.43
    EMA 20$30.79
    EMA 50$28.38
    EMA 200$119.26

    MACD

    Line: 2.48Signal: 2.90Hist: -0.42

    ADX

    ADX: 57.9+DI: 18.5-DI: 9.0

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down4.0
    PSAR$30.06

    Bollinger Bands

    Upper Band$35.82
    Lower Band$28.11
    %B Position2409%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    59.9

    Momentum Oscillators

    Stoch %K55.6
    Stoch %D48.5
    Williams %R-52.0
    ROC (10d)-4.5%
    Momentum-1.55
    CCI (20d)46.8
    MFI (14d)52.0

    Volatility Measures

    ATR (14d)$3.06(9.4%)
    StdDev (20d)1.93
    Hist Vol75.0%(High)

    Volume Flow

    VWAP$32.93
    OBV3.6B
    AD Line6687.9B
    CMF (20d)0.056

    Volume Metrics

    Avg Vol (20d)26.9K
    Vol Ratio1.3x
    VWMA (20d)$31.79

    Pivot Points

    R3$38.93
    R2$37.14
    R1$35.44
    Pivot Point$33.65
    S1$31.95
    S2$30.16
    S3$28.46

    Advanced Oscillators

    TSI32.39
    Ultimate Osc52.1
    KST589.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$168,000$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$16,000$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0$-16,000$0$0$0N/A$0
    Operating Expenses$79.78M$14.59M$19.35M$13.43M$10.43M$14.86M$12.01M$5.86M$28.19M$11.22M$9.99M$6.09M
    R&D$64.46M$6.84M$12.60M$8.08M$6.55M$8.14M$5.83M$4.92M$4.15M$3.70M$3.43M$1.43M
    SG&A$16.63M$4.27M$3.63M$3.28M$3.34M$4.79M$4.28M$3.63M$4.70M$4.97M$4.97M$4.66M
    Operating Income$-79,782,000$-14,590,000$-19,353,000$-13,430,000$-10,427,000$-14,858,000$-12,012,000$-5,863,000$-28,192,000$-11,218,000$-9,986,000$-6,094,000
    Interest Income$584,000$160,000$227,000$300,000$311,000$406,000$536,000$683,000$823,000$887,000$1.01M$959,000
    Interest Expense$0$0$16.96M$58,000$5.55M$125,000$439,000$0$415,000$388,000$338,000$0
    Income Before Tax$-75,413,000$30.57M$-36,312,000$-13,488,000$-15,982,000$-14,983,000$-12,451,000$-5,479,000$-27,693,000$-11,118,000$-8,843,000$-5,351,000
    Income Tax Expense$75,000$-5,339,000$3.15M$-46,000$67,000$47,000$7,000$13,000$36,000$31,000$51,000$0
    Net Income$-75,488,000$35.91M$-39,458,000$-13,442,000$-16,049,000$-15,030,000$-12,458,000$-5,492,000$-27,729,000$-11,149,000$-8,894,000$-5,351,000
    EBITDA$-75,956,000$30.39M$-37,633,000$-13,988,000$-16,493,000$-15,712,000$-14,264,000$-6,668,000$-28,677,000$-12,223,000$-9,921,000$-7,021,000
    EBIT$-75,997,000$30.41M$-37,484,000$-13,788,000$-16,293,000$-15,389,000$-13,790,000$-6,162,000$-28,101,000$-11,617,000$-9,519,000$-6,310,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QNCX

    News

    Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026)

    Quince Therapeutics, Inc. (NASDAQ: QNCX) filed an EFFECT notice with the SEC on August 25, 2026, which became effective on August 24, 2026, at 4:00 P.M. The filing is an S-3 form with file number 333-297903. This SEC filing has a neutral impact and sentiment according to AI analysis.

    Stock Titan•8/25/26•
    Neutral

    Craig-Hallum Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $68

    Craig-Hallum has initiated coverage on Quince Therapeutics (QNCX.US) with a "Buy" rating. The firm has also set a target price of $68 for the company's stock.

    Moomoo•8/20/26•
    Bullish

    Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) with Buy Rating, $68 Price Target

    Craig-Hallum has initiated coverage on Quince Therapeutics (QNCX) with a Buy rating and a $68 price target, driven by the potential of its acquired drug candidate LAM-001. Despite having no revenue and a low GF Score™ of 24/100, the firm highlights the company's moderate financial strength and upcoming clinical trial data as key catalysts. Insider selling over the past year and the absence of guru ownership suggest caution for investors in this early-stage biotech.

    GuruFocus•8/20/26•
    Somewhat-Bullish

    LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Cuts Target Price to $98

    LifeSci Capital has reiterated its Buy rating for Quince Therapeutics (QNCX.US) but has adjusted its target price downwards to $98. This indicates continued confidence in the company's prospects, albeit with a revised valuation.

    Moomoo•8/19/26•
    Somewhat-Bearish

    Quince Therapeutics stock rating reiterated by Cantor Fitzgerald

    Cantor Fitzgerald reiterated an "Overweight" rating on Quince Therapeutics Inc. (NASDAQ:QNCX) with a $70.00 price target, highlighting the company's LAM-001 drug for pulmonary conditions. The firm remains positive on LAM-001 due to its direct lung delivery approach for well-understood drug pathways. Quince Therapeutics also plans a special stockholder meeting for share issuance related to Series C Preferred Stock conversion and has formed a Scientific Advisory Board for LAM-001 development.

    Investing.com•8/19/26•
    Bullish

    Frequently Asked Questions About QNCX

    Does QNCX pay dividends?
    Quince Therapeutics, Inc. (QNCX) does not currently pay a regular dividend.
    What is QNCX's market cap?
    Quince Therapeutics, Inc. (QNCX) has a market capitalization of $34.33M with a current stock price of $32.57.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In